Availability and quality of anti-malarials among private sector outlets in Myanmar in 2012: Results from a large, community-based, cross-sectional survey before a large-scale intervention

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Khin, Hnin Su Su ^a   Chen, Ingrid ^b   White, Chris ^a   Sudhinaraset, May ^b   McFarland, Willi ^b   Littrell, Megan ^a   Montagu, Dominic ^b   Aung, Tin ^a  

^a POPULATION SERVICES INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ACTwatch; Artemisinin based monotherapy; Drug resistance; Malaria; Myanmar; Private sector

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE;

ADULT; ARTICLE; COMMUNITY ASSESSMENT; CROSS-SECTIONAL STUDY; DRUG INDUSTRY; HEALTH CARE AVAILABILITY; HEALTH CARE PERSONNEL; HEALTH CARE PRACTICE; HEALTH CARE QUALITY; HEALTH CARE SURVEY; HUMAN; MALARIA FALCIPARUM; MONOTHERAPY; MYANMAR; PHARMACY; PLASMODIUM VIVAX MALARIA; PRACTICE GUIDELINE; PRIVATE HOSPITAL; RURAL AREA; URBAN AREA; ADOLESCENT; AGED; COMMERCIAL PHENOMENA; ECONOMICS; MALARIA; MIDDLE AGED; PRIVATE SECTOR; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; ARTEMISININS; COMMERCE; CROSS-SECTIONAL STUDIES; HUMANS; MALARIA; MIDDLE AGED; MYANMAR; PHARMACIES; PRIVATE SECTOR; YOUNG ADULT;

EID: 84937218829     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0778-0     Document Type: Article

References (18)

1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM et al (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620
2. WHO (2014) World malaria report. World Health Organization, Geneva
3. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R et al (2012) Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379:1960-1966
4. Takala-Harrison S, Jacob CG, Arze C, Cummings MP, Silva JC, Dondorp AM et al (2015) Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis 211:670-679
5. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S et al (2014) Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371:411-423
6. Smith Gueye C, Newby G, Hwang J, Phillips AA, Whittaker M, MacArthur JR et al (2014) The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion. Malar J 13:286
7. WHO (2011) Global plan for artemisinin resistance containment (GPARC). http://www.who.int/malaria/publications/atoz/artemisinin-resistance-containment-2011.pdf. Accessed 06 January 2015
8. PSI Myanmar (2013) Tracking changes in Myanmar's antimalarial market in the context of drug resistance containment. http://www.actwatch.info/sites/default/files/content/publications/attachments/Tracking%20changes%20in%20Myanmar%27s%20antimalarial%20market%20in%20the%20context%20of%20drug%20resistance%20containment.pdf. Accessed 06 January 2015
9. Shewchuk T, O'Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D (2011) The ACTwatch project: methods to describe anti-malarial markets in seven countries. Malar J 10:325
10. Health Action International (2003) Medicine prices: a new approach to measurement. Working draft for field testing and revision, 2003. http://www.haiweb.org/medicineprices/manual/manuals/MedicinePrices.pdf. Accessed 06 January 2015
11. Guideline on Submission of Documentation for Prequalification of Multisource (generic) Finished Pharmaceutical Products (FPPs) approved by Stringent Regulatory Authorities (SRAs) (2011). http://apps.who.int/prequal/info-applicants/Guidelines/PQProcGenericSRA-July2011.pdf. Accessed 26 June 2015
12. WHO (2015) Guidelines for the treatment of malaria, 3rd edn. http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127-eng.pdf?ua=1. Accessed 26 June 2015
13. Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D et al (2009) Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PLoS One 4:e6857
14. Aung T, White C, Montagu D, McFarland W, Hlaing T, Khin HSS et al (2015) Improving uptake and quality among informal providers using rapid diagnostic tests in Myanmar: an intervention of provider incentives. Malar J 14:105
15. Chen IT, Aung T, Thant NN, Sudhinaraset M, Kahn JG (2015) Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar. Malar J 14:55
16. Sudhinaraset M, Briegleb C, Aung M, Khin HS, Aung T (2015) Motivation and challenges for use of malaria rapid diagnostic tests among informal providers in Myanmar: a qualitative study. Malar J 14:61
17. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E et al (2011) Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J 10:326
18. Littrell M, Gatakaa H, Phok S, Allen H, Yeung S, Chuor CM et al (2011) Case management of malaria fever in Cambodia: results from national anti-malarial outlet and household surveys. Malar J 10:328